Literature DB >> 29129717

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Hai-Tsang Huang1, Dennis Dobrovolsky1, Joshiawa Paulk2, Guang Yang3, Ellen L Weisberg2, Zainab M Doctor1, Dennis L Buckley2, Joong-Heui Cho4, Eunhwa Ko4, Jaebong Jang1, Kun Shi5, Hwan Geun Choi4, James D Griffin6, Ying Li7, Steven P Treon8, Eric S Fischer1, James E Bradner6, Li Tan9, Nathanael S Gray10.   

Abstract

Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degradation represent an emerging pharmacological strategy. A major unanswered question is how generally applicable this strategy is to all protein targets. In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quantitative proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable. This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degradation requires more than target engagement. The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment. Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clinical developments.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BTK; FLT3; chemoproteomics; drug design; kinase; protein degradation

Mesh:

Substances:

Year:  2017        PMID: 29129717      PMCID: PMC6427047          DOI: 10.1016/j.chembiol.2017.10.005

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  102 in total

1.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

2.  A MedChem toolbox for cereblon-directed PROTACs.

Authors:  Christian Steinebach; Izidor Sosič; Stefanie Lindner; Aleša Bricelj; Franziska Kohl; Yuen Lam Dora Ng; Marius Monschke; Karl G Wagner; Jan Krönke; Michael Gütschow
Journal:  Medchemcomm       Date:  2019-05-28       Impact factor: 3.597

Review 3.  Substrate selection by the proteasome through initiation regions.

Authors:  Takuya Tomita; Andreas Matouschek
Journal:  Protein Sci       Date:  2019-05-23       Impact factor: 6.725

Review 4.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 5.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

6.  Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.

Authors:  Rati Verma
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.

Authors:  Caroline A Foley; Frances Potjewyd; Kelsey N Lamb; Lindsey I James; Stephen V Frye
Journal:  ACS Chem Biol       Date:  2019-12-27       Impact factor: 5.100

Review 8.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 9.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

10.  ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation.

Authors:  Qi Zhang; Jingyu Zhang; Evripidis Gavathiotis
Journal:  ACS Chem Biol       Date:  2018-05-02       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.